(Q37614203)

21 August 2017

1 reference

title

Antiangiogenic therapies for high-grade glioma (English)

1 reference

21 August 2017

angiogenesis inhibitor

1 reference

3

Patrick Y Wen

1 reference

21 August 2017

Andrew D Norden

1

1 reference

PubMed ID

19826401

21 August 2017

Jan Drappatz

series ordinal

2

1 reference

PubMed ID

19826401

21 August 2017

language of work or name

English

0 references

publication date

13 October 2009

1 reference

21 August 2017

Nature Reviews Neurology

1 reference

21 August 2017

5

1 reference

21 August 2017

610-620

1 reference

21 August 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2009.159

21 August 2017

0 references

cites work

Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Malignant gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Angiogenesis as a therapeutic target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Angiogenesis in brain tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Transplacental carcinogenesis by stilbestrol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

The role of angiopoietins during angiogenesis in gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Platelet-derived growth factor (PDGF) and glial tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Interleukin-8 differentially regulates migration of tumor-associated and normal human brain endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

The role of myeloid cells in the promotion of tumour angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Cancer stem cells in radiation resistance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Making a tumour's bed: glioblastoma stem cells and the vascular niche.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

A perivascular niche for brain tumor stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Bevacizumab and irinotecan for recurrent oligodendroglial tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

VEGF-Trap: a VEGF blocker with potent antitumor effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Tumorigenesis and the angiogenic switch

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Thalidomide is an inhibitor of angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Therapeutic strategies for inhibiting invasion in glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Integrins in angiogenesis and lymphangiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

VEGF inhibition and renal thrombotic microangiopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Medical management of brain tumor patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Colon perforation during antiangiogenic therapy for malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Reversible posterior leukoencephalopathy syndrome in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Antiangiogenic strategies for treatment of malignant gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

High-grade glioma before and after treatment with radiation and Avastin: initial observations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Response criteria for phase II studies of supratentorial malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.159

Invasion as limitation to anti-angiogenic glioma therapy

31 March 2020

1 reference

12 December 2020

Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.

1 reference

12 December 2020

Positive and negative modulation of angiogenesis by VEGFR1 ligands

1 reference

12 December 2020

Tumor angiogenesis: therapeutic implications

1 reference

12 December 2020

Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells.

1 reference

12 December 2020

Acidic and basic fibroblast growth factors are present in glioblastoma multiforme

1 reference

12 December 2020

VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells

1 reference

12 December 2020

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

1 reference

12 December 2020

Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.

1 reference

12 December 2020

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

1 reference

12 December 2020

10.1038/NRNEUROL.2009.159

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19826401